Clinical frontiers of metabolic bone disorders: a comprehensive review

Abstract

Metabolic bone disease (MBD)encompasses various conditions that adversely impact bone health, such as osteoporosis, primary hyperparathyroidism, osteomalacia, and fluorosis disease. Effectively managing these disorders requires early detection and a focus on maintaining healthy nutritional habits. Dietary adjustments serve as a cornerstone, but supplementation of essential minerals like calcium, phosphate, and vitamin D is often necessary to support bone reabsorption and regeneration, and reduce fracture risk. Despite the effectiveness of these measures in many cases, hereditary bone diseases pose distinctive challenges due to genetic factors. Emerging technologies that provide higher-resolution insights into bone architecture and quality are now complementing traditional diagnostic tools like dual-energy X-ray absorptiometry (DXA). Moreover, the therapeutic landscape has transformed with the introduction of newer agents that not only halt bone loss but also stimulate bone formation. These agents promise better outcomes with reduced side effects, catering to a wider patient population. However, the management of MBDs remains multifaceted, necessitating individualized approaches based on the patient’s clinical profile. As the global prevalence of MBDs, especially osteoporosis, continues to soar, it becomes imperative for clinicians to stay abreast with the evolving paradigms. This review serves as a bridge between historical knowledge and recent discoveries, offering a holistic perspective on the challenges and opportunities in the domain of MBDs.

Keywords

MBDs / osteoporosis / osteomalacia / fluorosis / hyperparathyroidism / treatments

References

[1] Gass M.Preventing osteoporosis-related fractures: an overview.Am J Med2006;119:S3-11

[2] Sözen T,Başaran NÇ.An overview and management of osteoporosis.Eur J Rheumatol2017;4:46-56 PMCID:PMC5335887

[3] Harada S.Control of osteoblast function and regulation of bone mass.Nature2003;423:349-55

[4] Kanis JA,Rizzoli R.Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF)Correction to: European guidance for the diagnosis and management of osteoporosis in postmenopausal women.Osteoporos Int2020;31:209

[5] Iolascon G,Toro G,Liguori S.Pharmacological therapy of osteoporosis: what's new?.Clin Interv Aging2020;15:485-91. PMCID:PMC7105363

[6] Pinkerton JV.Combination therapy for treatment of osteoporosis: a review.Am J Obstet Gynecol2007;197:559-65

[7] Clynes MA,Curtis EM,Dennison EM.The epidemiology of osteoporosis.Br Med Bull2020;133:105-17 PMCID:PMC7115830

[8] Ansari MD,Solanki P.Fabrication and optimization of raloxifene loaded spanlastics vesicle for transdermal delivery.J Drug Deliv Sci Tec2022;68:103102.

[9] Ogbole OO,Segun PA,Adeniji AJ.In vitro antiviral activity of twenty-seven medicinal plant extracts from Southwest Nigeria against three serotypes of echoviruses.Virol J2018;15:110 PMCID:PMC6052623

[10] Palacios S,de Villiers TJ.Bazedoxifene Study GroupA 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture.Menopause2015;22:806-13

[11] Nuti R,Checchia G.Guidelines for the management of osteoporosis and fragility fractures.Intern Emerg Med2019;14:85-102 PMCID:PMC6329834

[12] Murthy A,Kathuria H.Oral Bioavailability Enhancement of Raloxifene with Nanostructured Lipid Carriers.Nanomaterials2020;10:1085. PMCID:PMC7353254

[13] Saini D,Ali MM,Ali J.Formulation, development and optimization of raloxifene-loaded chitosan nanoparticles for treatment of osteoporosis.Drug Deliv2015;22:823-36

[14] Uemura Y,Miyazaki T.Adequate Treatment of Osteoporosis (A-TOP) research groupStudy design of multi-center, open-label randomized controlled, head-to-head trial comparing minodronic acid and raloxifene: Japanese osteoporosis intervention trial (JOINT)-04.J Bone Miner Metab2019;37:491-5.

[15] Turner AS.Animal models of osteoporosis--necessity and limitations.Eur Cell Mater2001;1:66-81

[16] Tsuruoka S,Kaneda T,Fujimura A.Dosing time-dependent effect of raloxifene on plasma fibrinogen concentration in ovariectomized rats.Chronobiol Int2008;25:808-18

[17] Mahmood S,Chatterjee B.Transdermal delivery of raloxifene HCl via ethosomal system: Formulation, advanced characterizations and pharmacokinetic evaluation.Int J Pharm2018;542:36-46

[18] Yedavally-Yellayi S,Patalinghug EM.Update on osteoporosis.Prim Care2019;46:175-90

[19] Xia B,Zhou J,Feng L.Identification of potential pathogenic genes associated with osteoporosis.Bone Joint Res2017;6:640-8 PMCID:PMC5935809

[20] Zakir F,Farooq U.Design and development of a commercially viable in situ nanoemulgel for the treatment of postmenopausal osteoporosis.Nanomedicine2020;15:1167-87

[21] Ahmad N,Kushwaha P.Quercetin-loaded solid lipid nanoparticles improve osteoprotective activity in an ovariectomized rat model: a preventive strategy for post-menopausal osteoporosis.RSC Adv2016;6:97613-28

[22] Lüthje P,Tavast N,Kataja M.Evaluation of minimal fracture liaison service resource: costs and survival in secondary fracture prevention-a prospective one-year study in South-Finland.Aging Clin Exp Res2021;33:3015-27.

[23] Armstrong MJ.Diagnosis and treatment of parkinson disease: a review.JAMA2020;323:548-60

[24] Morita M,Iwasaki R.Selective estrogen receptor modulators suppress Hif1α protein accumulation in mouse osteoclasts.PLoS One2016;11:e0165922. PMCID:PMC5089792

[25] Fink HA,Forte ML.Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: a systematic review.Ann Intern Med2019;171:37-50

[26] Lorentzon M.Treating osteoporosis to prevent fractures: current concepts and future developments.J Intern Med2019;285:381-94

[27] Yanik B,Yanik T.The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women.Ren Fail2007;29:471-6

[28] Takashi Y,Fukumoto S.FGF23 and hypophosphatemic rickets/osteomalacia.Curr Osteoporos Rep2021;19:669-75

[29] Reginato AJ.Musculoskeletal manifestations of osteomalacia and rickets.Best Pract Res Clin Rheumatol2003;17:1063-80

[30] Fukumoto S.FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.J Mol Endocrinol2021;66:R57-65

[31] Manios Y,Lambrinou CP.Food4Me StudyAssociations of vitamin D status with dietary intakes and physical activity levels among adults from seven European countries: the Food₄Me study.Eur J Nutr2018;57:1357-68.

[32] Minisola S,Pepe J,Cipriani C.Osteomalacia and Vitamin D status: a clinical update 2020.JBMR Plus2021;5:e10447 PMCID:PMC7839817

[33] Endo I,Ozono K.Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.Bone2008;42:1235-9

[34] Kinoshita Y.X-linked hypophosphatemia and FGF23-related hypophosphatemic diseases: prospect for new treatment.Endocr Rev2018;39:274-91.

[35] Goldsweig BK.Hypophosphatemic rickets: lessons from disrupted FGF23 control of phosphorus homeostasis.Curr Osteoporos Rep2015;13:88-97.

[36] Hutchison FN.Osteomalacia and rickets.Semin Nephrol1992;12:127-45.

[37] Marques JVO,Borba VZC.New treatments for rare bone diseases: hypophosphatemic rickets/osteomalacia.Arch Endocrinol Metab2022;66:658-65. PMCID:PMC10118827

[38] Vilaca T,Smith C,Eastell R.Osteomalacia as a Complication of Intravenous Iron Infusion: a systematic review of case reports.J Bone Miner Res2022;37:1188-99 PMCID:PMC9322686

[39] Kaszczewska M,Kaszczewski P.Cystic parathyroid adenomas as a risk factor for severe hypercalcemia.J Clin Med2023;12:4939 PMCID:PMC10420109

[40] Marques JV, Moreira CA. Primary hyperparathyroidism.Best Pract Res Clin Rheumatol2020;34:101514

[41] Mukherjee S,Bhadada SK.Characterization of primary hyperparathyroidism based on target organ involvement: An analysis from the Indian PHPT registry.Clin Endocrinol2023;99:158-64

[42] Bilezikian JP,Silverberg SJ.International Workshop on Primary HyperparathyroidismEvaluation and management of primary hyperparathyroidism: summary statement and guidelines from the fifth international workshop.J Bone Miner Res2022;37:2293-314

[43] Minisola S,Belaya Z.Epidemiology, pathophysiology, and genetics of primary hyperparathyroidism.J Bone Miner Res2022;37:2315-29 PMCID:PMC10092691

[44] Bilezikian JP,Bandeira F.Management of primary hyperparathyroidism.J Bone Miner Res2022;37:2391-403

[45] Kowalski GJ,Żądło D,Gawrychowski J.Primary hyperparathyroidism.Endokrynol Pol2020;71:260-70

[46] Samy JVRA,Balasubramanian C.Effect of a polyherbal formulation on L-thyroxine induced hyperthyroidism in a rat model: in vitro and in vivo analysis and identification of bioactive phytochemicals.Int J Biol Macromol2023;237:124140

[47] Juhlin CC.Genomics and epigenomics in parathyroid neoplasia: from bench to surgical pathology practice.Endocr Pathol2021;32:17-34 PMCID:PMC7960610

[48] Fraser WD.Hyperparathyroidism.Lancet2009;374:145-58

[49] Aasenden R.Effects of fluoride supplementation from birth on human deciduous and permanent teeth.Arch Oral Biol1974;19:321-6

[50] Srivastava S.Fluoride in drinking water and skeletal fluorosis: a review of the global impact.Curr Environ Health Rep2020;7:140-6

[51] Browne D,O'Mullane D.Fluoride metabolism and fluorosis.J Dent2005;33:177-86

[52] Fejerskov O,Baelum V.The nature and mechanisms of dental fluorosis in man.J Dent Res1990;69 Spec No:692-700; discussion 721.

[53] Pandit J,Jain NK.Miconazole nitrate bearing ultraflexible liposomes for the treatment of fungal infection.J Liposome Res2014;24:163-9

[54] Mantovani A,Zoppini G.Association between nonalcoholic fatty liver disease and reduced bone mineral density in children: a meta-analysis.Hepatology2019;70:812-23

[55] Targher G,Rossini M.Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link?.J Endocrinol Invest2015;38:817-25.

[56] Filip R,Bieńko M.Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis.Clin Interv Aging2018;13:1879-91. PMCID:PMC6174895

[57] Pan B,Zhao P.Relationship between prevalence and risk of osteoporosis or osteoporotic fracture with non-alcoholic fatty liver disease: a systematic review and meta-analysis.Osteoporos Int2022;33:2275-86

[58] Wang YD,Qi XY.New insight of obesity-associated NAFLD: dysregulated "crosstalk" between multi-organ and the liver?.Genes Dis2023;10:799-812.

[59] Vachliotis ID,Goulas A,Polyzos SA.Nonalcoholic fatty liver disease and osteoporosis: a potential association with therapeutic implications.Diabetes Obes Metab2022;24:1702-20

[60] Rahimi L,Ismail-Beigi F.Glucocorticoid-induced fatty liver disease.Diabetes Metab Syndr Obes2020;13:1133-45 PMCID:PMC7171875

[61] Eslam M,Francque S.Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight.Nat Rev Gastro Hepat2022;19:638-51.

[62] Barchetta I,Cavallo MG.Vitamin D and metabolic dysfunction-associated fatty liver disease (MAFLD): an update.Nutrients2020;12:3302. PMCID:PMC7693133

[63] Fabbrini E.Hepatic steatosis as a marker of metabolic dysfunction.Nutrients2015;7:4995-5019 PMCID:PMC4488828

[64] Staufer K.Steatotic liver disease: metabolic dysfunction, alcohol, or both?.Biomedicines2023;11:2108 PMCID:PMC10452742

[65] Camacho PM.Metabolic bone diseases: a case-based approach. Switzerland: Springer Cham; 2019.

[66] Brickley MB,Mays S.The bioarchaeology of metabolic bone disease. Academic Press; 2020.

[67] Charoenngam N,Shirvani A.Hereditary metabolic bone diseases: a review of pathogenesis, diagnosis and management.Genes2022;13:1880. PMCID:PMC9601711

[68] Charoenngam N,Holick MF.Diagnosis and management of pediatric metabolic bone diseases associated with skeletal fragility.Curr Opin Pediatr2020;32:560-73

[69] Nordic nutrition recommendations 2023. Available from: https://pub.norden.org/nord2023-003/ [Last accessed on 25 Dec 2023]

[70] NORDIC NUTRITION RECOMMENDATIONS 2023. Vitamin D. Available from: https://pub.norden.org/nord2023-003/vitamin-d-.html [Last accessed on 25 Dec 2023]

[71] Nurmi-Lüthje I,Paattiniemi EL.Remarkable improvement in serum 25-hydroxyvitamin levels among hip fracture patients over a 12-year period: a prospective study in South-eastern Finland.Osteoporos Int2018;29:837-45

[72] Creo AL,Buchholtz JA.Prevalence of metabolic bone disease in tube-fed children receiving elemental formula.Horm Res Paediatr2018;90:291-8.

[73] Young CM,Manikowski KJ,Skinner BW.Chapter 34 - Drugs for metabolic bone disease. A worldwide yearly survey of new data in adverse drug reactions. Elsevier; 2022. pp. 471-81.

[74] Langdahl BL.Overview of treatment approaches to osteoporosis.Br J Pharmacol2021;178:1891-906

[75] Khuroo T,Talegaonkar S,Panda AK.Topotecan-tamoxifen duple PLGA polymeric nanoparticles: investigation of in vitro, in vivo and cellular uptake potential.Int J Pharm2014;473:384-94

[76] Gong L,Yang N,Zhang LK.Raloxifene prevents early periprosthetic bone loss for postmenopausal women after uncemented total hip arthroplasty: a randomized placebo-controlled clinical trial.Orthop Surg2020;12:1074-83 PMCID:PMC7454213

[77] Delmas PD,Mitlak BH.Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.N Engl J Med1997;337:1641-7